Trial Profile
A Randomized, Double-blind Study of Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Fimasartan (Primary)
- Indications Coronary disorders
- Focus Therapeutic Use
- Acronyms FIMA-DEFER
- 19 Jun 2018 Status changed from active, no longer recruiting to discontinued.
- 23 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Nov 2015 Planned End Date changed from 1 Jun 2013 to 1 May 2019 as reported by ClinicalTrials.gov record.